Form 4: CVRx Director Kevin Ballinger Granted 19,554 Stock Options

CVRx, Inc. Director Kevin J. Ballinger was granted 19,554 stock options with an exercise price of $6.76, vesting by June 2026.

Summary

• Director Kevin J. Ballinger of CVRx, Inc. was granted 19,554 stock options.
• The stock options have an exercise price of $6.76 per share.
• These options are scheduled to vest on the earlier of June 3, 2026, or the Issuer's 2026 annual meeting of stockholders.
• The expiration date for these stock options is June 3, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of continued commitment and aligns the director's interests with long-term shareholder value, representing a routine and expected compensation event.

Positives

• The grant of stock options to Director Kevin J. Ballinger aligns his interests with those of shareholders, incentivizing long-term performance and commitment to the company's success.

Future Outlook

The stock options granted to Director Ballinger are set to vest by June 3, 2026, or the 2026 annual meeting, aligning his future compensation with the company's performance over this period and indicating a continued commitment to the company's long-term strategy.

Industry Context

The granting of stock options to directors is a common practice in the medical device and broader technology industries to attract, retain, and incentivize key personnel, aligning their long-term interests with company performance and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the medical technology sector, aiming to align director incentives with long-term shareholder value. Specific comparisons to peer companies like Medtronic or Boston Scientific would require detailed compensation plan analysis not available in this filing.

Related Party Transactions

• The grant of stock options to Director Kevin J. Ballinger constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to better long-term performance and strategic decisions.

Next Steps

• The stock options are expected to vest on the earlier of June 3, 2026, or CVRx's 2026 annual meeting of stockholders.

Key Dates

Keywords

CVRx, CVRX, stock options, insider transaction, Form 4, beneficial ownership, director compensation, equity grant